Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
KaloBios Is Back From The Dead
by Lisa M. Jarvis
November 23, 2015
| A version of this story appeared in
Volume 93, Issue 46
Less than a week after announcing it was folding, KaloBios Pharmaceuticals has a chance to live on. An investor group led by Martin Shkreli, the controversial CEO of Turing Pharmaceuticals, has acquired more than 50% of KaloBios’s shares and has approached the biotech with a proposal to continue its operations. Shares of KaloBios, which traded below $1.00 on the day it announced the liquidation, surged as high as $13.00 on news of Shkreli’s investment. KaloBios has struggled since announcing in January the failure of a Phase II study of an antibody fragment to treat Pseudomonas infections in people with cystic fibrosis.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X